☰

Mark T. Preissler, Ph.D. - Publications

Affiliations: 
2004 Albany Medical College of Union University 
Area:
Immunology
Tree Info Grants Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Andersen NJ, Mondal TK, Preissler MT, Freed BM, Stockinger S, Bell E, Druschel C, Louis GM, Lawrence DA. Detection of immunoglobulin isotypes from dried blood spots. Journal of Immunological Methods. 404: 24-32. PMID 24333851 DOI: 10.1016/J.Jim.2013.12.001  0.32
2005 Adamova E, Walsh MC, Gosselin DR, Hale K, Preissler MT, Graziano RF, Gosselin EJ. Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunological Investigations. 34: 417-29. PMID 16304730 DOI: 10.1080/08820130500265372  0.672
2005 Preissler MT, Kaiser L, Drake JR, Gosselin EJ. Low-level signaling generated by FcgammaRIIB-B cell receptor co-ligation establishes a state of global B cell receptor nonresponsiveness. Immunological Investigations. 34: 53-70. PMID 15773572 DOI: 10.1081/1MM-200047385  0.645
2005 Preissler MT, Kaiser L, Drake JR, Gosselin EJ. Low-level signaling generated by FcγRIIB-B cell receptor co-ligation establishes a state of global B cell receptor nonresponsiveness Immunological Investigations. 34: 53-70. DOI: 10.1081/Imm-47385  0.647
2003 Preissler MT, Walsh MC, Banas JA, Gallagher DJ, Gosselin EJ. Generation of a human IgG3-streptavidin fusion protein. Implications for the inhibition and elimination of auto-reactive B cells. Human Antibodies. 12: 77-92. PMID 14646036 DOI: 10.3233/Hab-2003-12304  0.687
2003 Jordan RA, Preissler MT, Banas JA, Gosselin EJ. Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation. Clinical and Diagnostic Laboratory Immunology. 10: 339-44. PMID 12738628 DOI: 10.1128/Cdli.10.3.339-344.2003  0.638
2003 Walsh MC, Banas JA, Mudzinski SP, Preissler MT, Graziano RF, Gosselin EJ. A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen. Biomolecular Engineering. 20: 21-33. PMID 12485681 DOI: 10.1016/S1389-0344(02)00089-8  0.665
2003 Walsh MC, Banas JA, Mudzinski SP, Preissler MT, Graziano RF, Gosselin EJ. A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcγRI-streptavidin construct and microspheres coated with biotinylated-antigen Biomolecular Engineering. 20: 21-33. DOI: 10.1016/S1389-0344(02)00089-8  0.667
2001 Plitnick LM, Jordan RA, Banas JA, Jelley-Gibbs DM, Walsh MC, Preissler MT, Gosselin EJ. Lipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2. Clinical and Diagnostic Laboratory Immunology. 8: 972-9. PMID 11527813 DOI: 10.1128/Cdli.8.5.972-979.2001  0.629
Show low-probability matches.